OBJECTIVE: Liver X-activated receptor alpha (LXRalpha) regulates multiple genes controlling cholesterol metabolism and transport. To clarify its role in atherogenesis, we established a monoclonal antibody recognizing native human LXRalpha protein and studied the expression pattern in human atherosclerotic lesions. METHODS AND RESULTS: A novel monoclonal antibody PPZ0412 was raised against the ligand-binding domain of LXRalpha, which can be used for immunostaining of human LXRalpha protein. LXRalpha protein was detected in the nucleus of macrophages in the liver, spleen, or lung and also in hepatocytes and adipocytes. In atherosclerotic lesions, the LXRalpha protein was detected in macrophages positive for scavenger receptor class A and/or CD68. CONCLUSIONS: In the human body, the LXRalpha protein is highly expressed in macrophage lineage cells and foam cells in atherosclerotic lesions and is identified as a target for intervention in atherosclerotic disease.
OBJECTIVE: Liver X-activated receptor alpha (LXRalpha) regulates multiple genes controlling cholesterol metabolism and transport. To clarify its role in atherogenesis, we established a monoclonal antibody recognizing native humanLXRalpha protein and studied the expression pattern in humanatherosclerotic lesions. METHODS AND RESULTS: A novel monoclonal antibody PPZ0412 was raised against the ligand-binding domain of LXRalpha, which can be used for immunostaining of humanLXRalpha protein. LXRalpha protein was detected in the nucleus of macrophages in the liver, spleen, or lung and also in hepatocytes and adipocytes. In atherosclerotic lesions, the LXRalpha protein was detected in macrophages positive for scavenger receptor class A and/or CD68. CONCLUSIONS: In the human body, the LXRalpha protein is highly expressed in macrophage lineage cells and foam cells in atherosclerotic lesions and is identified as a target for intervention in atherosclerotic disease.
Authors: Fulvio Morello; Rudolf A de Boer; Knut R Steffensen; Massimiliano Gnecchi; Jeffrey W Chisholm; Frans Boomsma; Leonard M Anderson; Richard M Lawn; Jan-Ake Gustafsson; Marco Lopez-Ilasaca; Richard E Pratt; Victor J Dzau Journal: J Clin Invest Date: 2005-07 Impact factor: 14.808
Authors: Radmila Feldmann; Cornelius Fischer; Vitam Kodelja; Sarah Behrens; Stefan Haas; Martin Vingron; Bernd Timmermann; Anne Geikowski; Sascha Sauer Journal: Nucleic Acids Res Date: 2013-02-07 Impact factor: 16.971
Authors: Noelia A-Gonzalez; Jose A Guillen; Germán Gallardo; Mercedes Diaz; Juan V de la Rosa; Irene H Hernandez; Maria Casanova-Acebes; Felix Lopez; Carlos Tabraue; Susana Beceiro; Cynthia Hong; Pedro C Lara; Miguel Andujar; Satoko Arai; Toru Miyazaki; Senlin Li; Angel L Corbi; Peter Tontonoz; Andres Hidalgo; Antonio Castrillo Journal: Nat Immunol Date: 2013-06-16 Impact factor: 25.606